Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) was submitted on July 12, 2023. The report serves to furnish documents related to the Company's Annual General Meeting of Shareholders scheduled for August 24, 2023, in Tel Aviv, Israel.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing containing meeting notices and proxy materials rather than a financial report.
Material Changes
No material financial changes versus the prior comparable period are disclosed in this filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or discussion of risks and contingencies. It strictly outlines the logistics for the upcoming shareholder meeting, including the Notice and Proxy Statement (Exhibit 99.1) and the Proxy Card (Exhibit 99.2).
Key Facts for Investors to Verify
- Verify the date, time, and location of the Annual General Meeting (August 24, 2023, at Goldfarb Gross Seligman & Co., Tel Aviv).
- Review the attached Notice and Proxy Statement for specific proposals to be voted upon.
- Confirm the procedures for voting in person or by proxy as detailed in the exhibits.
- Note that this filing does not contain updated financial performance data.